WeVote
Log In

Bill

Bill

HB 1643

Modifies provisions relating to alternative therapies and treatments, including psilocybin

2026 Regular Session Introduced by Matthew Overcast

Missouri bill modifying psilocybin regulations to permit alternative therapeutic uses within state law, reflecting broader national reconsideration of psychedelic treatment protocols.

Prefiled (H)
#drugsandcontrolledsubstances #healthcare #mentalhealth #departmentof
0
WeVote Research Nonpartisan
Bill Summary · HB 1643

Legislative bill overview

HB 1643 modifies Missouri state law regarding alternative therapies and treatments, with specific focus on psilocybin—a controlled substance found in certain mushrooms with psychoactive properties. The bill has been prefiled but lacks detailed public information about its specific provisions at this stage of the legislative process.

Why is this important

Psilocybin regulation directly affects potential therapeutic research, criminal justice policy, and public health approaches in Missouri. This legislative action reflects growing national interest in psychedelic-assisted therapy, particularly for treatment-resistant depression, PTSD, and end-of-life care, though federal law still classifies psilocybin as a Schedule I controlled substance.

Potential points of contention

  • Federal-state legal conflict: Missouri cannot legalize psilocybin outright due to federal prohibition, creating ambiguity about what "modifications" actually permit
  • Medical framework questions: Whether the bill creates clinical research exemptions, therapeutic access pathways, or merely decriminalization provisions—each with vastly different implications
  • Public safety concerns: Opposition from law enforcement and some medical organizations regarding safety protocols, dosing standards, and oversight mechanisms

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.